Connect with us

Hi, what are you looking for?


Whales go bullish on SAVA stock: where to buy the Cassava Sciences stock

The Cassava Sciences stock (NASDAQ: SAVA) has been very bullish over the past month. It has gained more than 58% in a span of 30 days and investors are still bullish on the stock.

Yesterday, a whale with a lot of money to spend took a noticeably bullish stance on the SAVA stock. Besides the whale, the majority of traders have opened call positions on the SAVA stock compared to put options hinting at how optimistic investors are about the stock.

To help stock investors who want to invest in the SAVA stock, Invezz has created a brief guide on where they can buy it.

To find out more, please continue reading.

Where to buy Cassava Sciences stock                     


eToro is a multi-asset investment platform with more than 2000 assets, including FX, stocks, ETF’s, indices and commodities. eToro users can connect with, learn from, and copy or get copied by other users. Buying stocks on eToro is free and you can invest with as little as $50.

Register with eToro instantly

IG Markets

The world-leading online trading and investments provider giving clients access to opportunities across thousands of financial markets through our intuitive platforms and apps.

Register with IG Markets instantly

What is Cassava Sciences?

Cassava Sciences is a clinical-stage biotechnology company that develops drugs for neurodegenerative diseases like Alzheimer’s. It was previously known as Pain Therapeutics, Inc.

Its top therapeutic products include simufilam, which is a small molecule drug, and SavaDx, which is a blood-based diagnostic drug for detecting Alzheimer’s disease.

It is a publicly-traded company and it trades on Nasdaq, under the ticker SAVA. Nasdaq recently announced that it is starting to offer crypto custody via its new Digital Assets unit.

Should I buy the SAVA stock today?

If you are looking to take advantage of a stock whose price has largely gained over the past month, then the SAVA stock could be a good choice.

However, it is still not clear how far the current bull trend will go.

Cassava Sciences stock price prediction

Based on a forecast from several stock analysts, the SAVA stock is expected to continue rising in the coming days and possibly surge above $40 by the end of this week.

$SAVA social media trends

– I wouldn’t be surprised with a 80% gain tomorrow – shorts will fuel it and everyone knows this is a 100 dollar stock –

key indicator is a 40+ open.

— Joseph Bowen (@Jos_bowen) September 20, 2022

$SAVA Cassava Sciences was up over 28% today after a Freedom of Information request letter was issued. Also called in the watchlist prior to Monday when it was trading around $30.

— TradingSecrets (@TradingSecrets7) September 20, 2022

The post Whales go bullish on SAVA stock: where to buy the Cassava Sciences stock appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like


    Solana (SOL/USD) is enormously underrated as a cryptocurrency project, even with its hiccups – including the latest exploit on one of the ecosystem apps....

    Editor's Pick

    The new eSIM infrastructure will help modernise the IoT connectivity market with fast, secure connections and reduced vendor lock-in. 1oT, a tech startup from...


    The latest Job Openings and Labor Turnover Survey from the Bureau of Labor Statistics shows the total number of job openings in the economy...


    U.S. District Court Judge Reed O’Connor recently ruled to uphold the rights of employers granted in the Religious Freedom Restoration Act, rather than uphold...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023